And phytohemagglutinin (PHA) was then used to activate PBMCs from CD69low NSCLC patients and healthy volunteers to verify the predisposing role of CD69high expression for death and exhaustion of lymphocytes in PD-1 mAb immunotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.